<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0185-3325</journal-id>
<journal-title><![CDATA[Salud mental]]></journal-title>
<abbrev-journal-title><![CDATA[Salud Ment]]></abbrev-journal-title>
<issn>0185-3325</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0185-33252017000300111</article-id>
<article-id pub-id-type="doi">10.17711/sm.0185-3325.2017.014</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Therapeutic properties of cannabinoid drugs and marijuana in several disorders: A narrative review]]></article-title>
<article-title xml:lang="es"><![CDATA[Propiedades terapeúticas de los fármacos cannabinoides y de la marihuana en distintas patologías: Revisión narrativa]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nanni Alvarado]]></surname>
<given-names><![CDATA[Ricardo Iván]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martín del Campo Sánchez]]></surname>
<given-names><![CDATA[Raúl]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villamil Salcedo]]></surname>
<given-names><![CDATA[Valerio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Comisión Nacional Contra las Adicciones Dirección General Adjunta de Políticas y Programas contra las Adicciones ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Comisión Nacional Contra las Adicciones Dirección General de Políticas y Programas contra las Adicciones ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz Departamento de Investigación Clínica ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>40</volume>
<numero>3</numero>
<fpage>111</fpage>
<lpage>118</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0185-33252017000300111&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0185-33252017000300111&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0185-33252017000300111&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background Anti-inflammatory, analgesic, anticonvulsant, and other effects have been attributed to cannabis, and so it has been widely used to treat several diseases.  Objective To assess the use and therapeutic effects of cannabinoid drugs and the cannabis plant in several diseases.  Method We carried out a narrative review of the literature that has reported the use of the cannabis plant (marijuana) and cannabinoid drugs (nabilone, cannabinol and dronabinol, among others). We conducted a search in Medline, Cochrane, SciELO and other web sites. Clinical, controlled, double-blind and randomized studies were included. The route of administration and the cannabinoid drugs used were assessed too.  Results Thirty-four studies were included. Nabilone was the cannabinoid drug more commonly used (12 studies), followed by delta-9-tetrahydrocannabinol (THC) (11 studies). It was also found that the marijuana plant and cannabinoid drugs were used to treat many symptoms or diseases. Two studies were reported for Gilles de la Tourette&#8217;s syndrome.  Discussion and conclusion Many scientific studies on the marijuana plant and cannabinoid drugs conclude that these are not as effective as conventional medications and thus their benefits should be taken with caution.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes A la planta de cannabis y a los fármacos cannabinoides se les han atribuido efectos antiinflamatorios, analgésicos y anticonvulsivantes, entre otros, y por ello se han utilizado para tratar diversas patologías.  Objetivo Evaluar el uso y los efectos terapéuticos de la planta de cannabis y los fármacos cannabinoides en diversas enfermedades.  Método Se utilizó un diseño descriptivo mediante la revisión narrativa de la literatura sobre el uso de la planta de cannabis (mariguana) y los fármacos cannabinoides (nabilona, cannabinol y dronabinol, entre otros) en los buscadores Medline, Cochrane, SciELO y otros. Se incluyeron sólo los estudios clínicos, controlados, doble ciego y aleatorizados, así como la vía de administración y el fármaco cannabinoide utilizado.  Resultados Treinta y cuatro estudios cumplieron con los criterios de inclusión. La nabilona fue el fármaco más empleado (12 estudios), seguida del delta-9-tetrahidrocannabinol (THC) (11 estudios). Tanto la planta como los fármacos cannabinoides se utilizaron para tratar diversos síntomas o enfermedades. Dos estudios reportaron su uso para el síndrome de Gilles de la Tourette.  Discusión y conclusión La mayoría de los estudios revisados indican que la efectividad de la planta de mariguana o de los fármacos cannabinoides no es superior a la de los fármacos convencionales y que sus beneficios deben tomarse con cautela.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Marijuana plant]]></kwd>
<kwd lng="en"><![CDATA[cannabinoid drugs]]></kwd>
<kwd lng="en"><![CDATA[therapeutic effects]]></kwd>
<kwd lng="en"><![CDATA[preclinical and clinical studies]]></kwd>
<kwd lng="en"><![CDATA[evidence-based medicine]]></kwd>
<kwd lng="en"><![CDATA[health policy]]></kwd>
<kwd lng="es"><![CDATA[Planta de mariguana]]></kwd>
<kwd lng="es"><![CDATA[fármacos cannabinoides]]></kwd>
<kwd lng="es"><![CDATA[efectos terapéuticos]]></kwd>
<kwd lng="es"><![CDATA[estudios clínicos]]></kwd>
<kwd lng="es"><![CDATA[medicina basada en pruebas]]></kwd>
<kwd lng="es"><![CDATA[política sanitaria]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection. A Randomized, Placebo-Controlled Clinical Trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abrams]]></surname>
<given-names><![CDATA[D. I.]]></given-names>
</name>
<name>
<surname><![CDATA[Hilton]]></surname>
<given-names><![CDATA[J. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Leiser]]></surname>
<given-names><![CDATA[R. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Shade]]></surname>
<given-names><![CDATA[S. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Elbeik]]></surname>
<given-names><![CDATA[T. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Aweeka]]></surname>
<given-names><![CDATA[F. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Deeks]]></surname>
<given-names><![CDATA[S. G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Annals of Internal Medicine]]></source>
<year>2003</year>
<volume>139</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>258-66</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barceloux]]></surname>
<given-names><![CDATA[D. G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Medical toxicology of drug abuse: synthesized chemicals and psychoactive plants]]></source>
<year>2012</year>
<publisher-loc><![CDATA[New Jersey ]]></publisher-loc>
<publisher-name><![CDATA[John Wiley & Sons]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[An Open&#8208;Label Comparison of Nabilone and Gabapentin as Adjuvant Therapy or Monotherapy in the Management of Neuropathic Pain in Patients with Peripheral Neuropathy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bestard]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Toth]]></surname>
<given-names><![CDATA[C. C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain Practice]]></source>
<year>2011</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>353-68</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mechanisms of NK cell activation: CD4+ T cells enter the scene]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bihl]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Germain]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Luci]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Braud]]></surname>
<given-names><![CDATA[V. M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cellular and Molecular Life Sciences]]></source>
<year>2011</year>
<volume>68</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>3457</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brady]]></surname>
<given-names><![CDATA[C. M.]]></given-names>
</name>
<name>
<surname><![CDATA[DasGupta]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Dalton]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Wiseman]]></surname>
<given-names><![CDATA[O. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Berkley]]></surname>
<given-names><![CDATA[K. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Fowler]]></surname>
<given-names><![CDATA[C. J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Multiple Sclerosis]]></source>
<year>2004</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>425-33</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabis for dyskinesia in Parkinson disease. A randomized double-blind crossover study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carroll]]></surname>
<given-names><![CDATA[C. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Bain]]></surname>
<given-names><![CDATA[P. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Teare]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Joint]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Wroath]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Zajicek]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurology]]></source>
<year>2004</year>
<volume>63</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1245-50</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<collab>Comisión Nacional contra las Adicciones</collab>
<source><![CDATA[El uso médico del cannabis ¿tiene sustento científico?]]></source>
<year>2014</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Comisión Nacional contra las Adicciones]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[S. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Buckman]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Medical oncology and tumor pharmacotherapy]]></source>
<year>1986</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-42</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crippa]]></surname>
<given-names><![CDATA[J. A. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Derenusson]]></surname>
<given-names><![CDATA[G. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[T. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Wichert-Ana]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Duran]]></surname>
<given-names><![CDATA[F. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Martin-Santos]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Filho]]></surname>
<given-names><![CDATA[A. S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Psychopharmacology]]></source>
<year>2011</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>121-30</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cunningham]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Bradley]]></surname>
<given-names><![CDATA[C. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Forrest]]></surname>
<given-names><![CDATA[G. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Hutcheon]]></surname>
<given-names><![CDATA[A. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Sneddon]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kaye]]></surname>
<given-names><![CDATA[S. B.]]></given-names>
</name>
</person-group>
<source><![CDATA[European Journal of Cancer and Clinical Oncology]]></source>
<year>1988</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>685-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The Problem of Cannabis Use: the Role of the Ministry of Health]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[del Bosque]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Huesca]]></surname>
<given-names><![CDATA[R. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[D. B.]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[A. D. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Mairena]]></surname>
<given-names><![CDATA[A. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarado]]></surname>
<given-names><![CDATA[R. N.]]></given-names>
</name>
</person-group>
<source><![CDATA[Salud Mental]]></source>
<year>2013</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>133-42</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devinsky]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Marsh]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Thiele]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Laux]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[The Lancet Neurology]]></source>
<year>2016</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>270-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[di Forti]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Marconi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Carra]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Fraietta]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Trotta]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Bonomo]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Stilo]]></surname>
<given-names><![CDATA[S. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[The Lancet Psychiatry]]></source>
<year>2015</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>233-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[di Marzo]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Piscitelli]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Mechoulam]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes-Perspectives in Drug Therapy]]></source>
<year>2011</year>
<page-range>75-104</page-range><publisher-loc><![CDATA[Berlin Heidelberg ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esfandyari]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Camilleri]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Busciglio]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Burton]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Baxter]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Zinsmeister]]></surname>
<given-names><![CDATA[A. R.]]></given-names>
</name>
</person-group>
<source><![CDATA[American Journal of Physiology-Gastrointestinal and Liver Physiology]]></source>
<year>2007</year>
<volume>293</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>G137-45</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The endogenous cannabinoid system and brain development]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Ruiz]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Berrendero]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[M. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Trends in neurosciences]]></source>
<year>2000</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14-20</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frank]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Serpell]]></surname>
<given-names><![CDATA[M. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Matthews]]></surname>
<given-names><![CDATA[J. N. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Kapur]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ]]></source>
<year>2008</year>
<volume>336</volume>
<numero>7637</numero>
<issue>7637</issue>
<page-range>199-201</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[R. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Adekanmi]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Waterfield]]></surname>
<given-names><![CDATA[M. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Waterfield]]></surname>
<given-names><![CDATA[A. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Zajicek]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[International Urogynecology Journal]]></source>
<year>2006</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>636-41</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Delta-9-Tetrahydrocannabinol as an Antiemetic for Patients Receiving Cancer Chemotherapy. A Comparison with Prochlorperazine and a Placebo]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frytak]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Moertel]]></surname>
<given-names><![CDATA[C. G.]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;fallon]]></surname>
<given-names><![CDATA[J. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Creagan]]></surname>
<given-names><![CDATA[E. T.]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;connell]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartau]]></surname>
<given-names><![CDATA[N. W.]]></given-names>
</name>
</person-group>
<source><![CDATA[Annals of Internal Medicine]]></source>
<year>1979</year>
<volume>91</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>825-30</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Pejovic]]></surname>
<given-names><![CDATA[M. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Thuaire]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kramar]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Wolff]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Biomedicine &amp; Pharmacotherapy]]></source>
<year>1982</year>
<volume>37</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>24-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabinoids, endocannabinoids, and cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hermanson]]></surname>
<given-names><![CDATA[D. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Marnett]]></surname>
<given-names><![CDATA[L. J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Metastasis Review]]></source>
<year>2011</year>
<volume>30</volume>
<numero>3-4</numero>
<issue>3-4</issue>
<page-range>599-612</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Endocannabinoid mechanisms of pain modulation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hohmann]]></surname>
<given-names><![CDATA[A. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Suplita]]></surname>
<given-names><![CDATA[R. L.]]></given-names>
</name>
</person-group>
<source><![CDATA[The AAPS Journal]]></source>
<year>2006</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>E693-708</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horváth]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Mukhopadhyay]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Haskó]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Pacher]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[The American Journal of Pathology]]></source>
<year>2012</year>
<volume>180</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>432-42</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox&#8211;Gastaut syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hussain]]></surname>
<given-names><![CDATA[S. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Weng]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Lay]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Sankar]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Epilepsy &amp; Behavior]]></source>
<year>2015</year>
<volume>47</volume>
<page-range>138-41</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hutcheon]]></surname>
<given-names><![CDATA[A. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[J. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Soukop]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[McArdle]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Welsh]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Cash]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<source><![CDATA[European Journal of Cancer and Clinical Oncology]]></source>
<year>1983</year>
<volume>19</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1087-90</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evidence for a novel functional role of cannabinoid CB2 receptors in the thalamus of neuropathic rats]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jhaveri]]></surname>
<given-names><![CDATA[M. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Elmes]]></surname>
<given-names><![CDATA[S. J. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Richardson]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Barrett]]></surname>
<given-names><![CDATA[D. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kendall]]></surname>
<given-names><![CDATA[D. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<source><![CDATA[European Journal of Neuroscience]]></source>
<year>2008</year>
<volume>27</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1722-30</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[S. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Durant]]></surname>
<given-names><![CDATA[J. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Greco]]></surname>
<given-names><![CDATA[F. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Robertone]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Treatment Reviews]]></source>
<year>1982</year>
<volume>9</volume>
<page-range>45-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kluin-Neleman]]></surname>
<given-names><![CDATA[J. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Neleman]]></surname>
<given-names><![CDATA[F. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Meuwissen]]></surname>
<given-names><![CDATA[O. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Maes]]></surname>
<given-names><![CDATA[R. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Veterinary and human toxicology]]></source>
<year>1979</year>
<volume>21</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>338-40</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The endogenous cardiac cannabinoid system: a new protective mechanism]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lamontagne]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Lepicier]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Lagneux]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Bouchard]]></surname>
<given-names><![CDATA[J. F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Archives des Maladies du Coeur et des Vaisseaux]]></source>
<year>2006</year>
<volume>99</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>242-6</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[Cannabidiol as an antipsychotic: a double-blind, controlled clinical trial of cannabidiol versus amisulpiride in acute schizophrenia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leweke]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Koethe]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Gerth]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<source><![CDATA[15th Annual Symposium on cannabinoids]]></source>
<year>2005</year>
<publisher-loc><![CDATA[Clearwater Beach, FL ]]></publisher-loc>
<publisher-name><![CDATA[International Cannabinoid Research Society]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lucraft]]></surname>
<given-names><![CDATA[H. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[M. K.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Radiology]]></source>
<year>1982</year>
<volume>33</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>621-2</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maas]]></surname>
<given-names><![CDATA[A. I.]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Henney]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Kassem]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Legrand]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Mangelus]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Knoller]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<source><![CDATA[The Lancet Neurology]]></source>
<year>2006</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-45</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Involvement of the endocannabinoid system in drug addiction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maldonado]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Valverde]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Berrendero]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Trends in neurosciences]]></source>
<year>2006</year>
<volume>29</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>225-32</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The biology of interleukin-2]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malek]]></surname>
<given-names><![CDATA[T. R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Annual Review of Immunology]]></source>
<year>2008</year>
<volume>26</volume>
<page-range>453-79</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maurer]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Henn]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Dittrich]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Hofmann]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[European Archives of Psychiatry and Clinical Neuroscience]]></source>
<year>1990</year>
<volume>240</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McAllister]]></surname>
<given-names><![CDATA[S. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Rigel]]></surname>
<given-names><![CDATA[T. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Horowitz]]></surname>
<given-names><![CDATA[M. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Desprez]]></surname>
<given-names><![CDATA[P. Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Molecular Cancer Therapeutics]]></source>
<year>2007</year>
<volume>6</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2921-7</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKallip]]></surname>
<given-names><![CDATA[R. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Jia]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Schlomer]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Warren]]></surname>
<given-names><![CDATA[J. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Nagarkatti]]></surname>
<given-names><![CDATA[P. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Nagarkatti]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Molecular Pharmacology]]></source>
<year>2006</year>
<volume>70</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>897-908</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meiri]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Jhangiani]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Vredenburgh]]></surname>
<given-names><![CDATA[J. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Barbato]]></surname>
<given-names><![CDATA[L. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[F. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[H. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Baranowski]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<source><![CDATA[Current Medical Research and Opinion]]></source>
<year>2007</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>533-43</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mortati]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Dworetzky]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Devinsky]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<source><![CDATA[Reviews in Neurological Diseases]]></source>
<year>2007</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>103-6</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of Tourette&#8217;s syndrome with &#916;9-tetrahydrocannabinol (THC): a randomized crossover trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Müller-Vahl]]></surname>
<given-names><![CDATA[K. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Koblenz]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Jöbges]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kolbe]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Daldrup]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Emrich]]></surname>
<given-names><![CDATA[H. M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacopsychiatry]]></source>
<year>2002</year>
<volume>35</volume>
<numero>02</numero>
<issue>02</issue>
<page-range>57-61</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[&#916;9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Müller-Vahl]]></surname>
<given-names><![CDATA[K. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Prevedel]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Theloe]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Kolbe]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Daldrup]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Emrich]]></surname>
<given-names><![CDATA[H. M.]]></given-names>
</name>
</person-group>
<source><![CDATA[The Journal of Clinical Psychiatry]]></source>
<year>2003</year>
<volume>64</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>459-65</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparative trial of the antiemetic effects of THC and haloperidol]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neidhart]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Gagen]]></surname>
<given-names><![CDATA[M. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[H. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[D. C.]]></given-names>
</name>
</person-group>
<source><![CDATA[The Journal of Clinical Pharmacology]]></source>
<year>1981</year>
<volume>21</volume>
<numero>S1</numero>
<issue>S1</issue>
</nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The analgesic properties of delta&#8208;9&#8208;tetrahydrocannabinol and codeine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Noyes]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Brunk]]></surname>
<given-names><![CDATA[S. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Avery]]></surname>
<given-names><![CDATA[D. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Canter]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Pharmacology &amp; Therapeutics]]></source>
<year>1975</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>84-9</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ostenfeld]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Price]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Albanese]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Bullman]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Guillard]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Milleri]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[The Clinical Journal of Pain]]></source>
<year>2011</year>
<volume>27</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>668-76</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain--a randomized controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinsger]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Schimetta]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Volc]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Hiermann]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Riederer]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Pölz]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<source><![CDATA[Wiener Klinische Wochenschrift]]></source>
<year>2006</year>
<volume>118</volume>
<numero>11-12</numero>
<issue>11-12</issue>
<page-range>327-35</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pooyania]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Ethans]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Szturm]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Perry]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Archives of Physical Medicine and Rehabilitation]]></source>
<year>2010</year>
<volume>91</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>703-7</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Potency of &#916;9&#8211;THC and other cannabinoids in cannabis in England in 2005: Implications for psychoactivity and pharmacology]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Potter]]></surname>
<given-names><![CDATA[D. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[M. B.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Forensic Sciences]]></source>
<year>2008</year>
<volume>53</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>90-4</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Press]]></surname>
<given-names><![CDATA[C. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Knupp]]></surname>
<given-names><![CDATA[K. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[K. E.]]></given-names>
</name>
</person-group>
<source><![CDATA[Epilepsy &amp; Behavior]]></source>
<year>2015</year>
<volume>45</volume>
<page-range>49-52</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Priestman]]></surname>
<given-names><![CDATA[S. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Priestman]]></surname>
<given-names><![CDATA[T. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Canney]]></surname>
<given-names><![CDATA[P. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Radiology]]></source>
<year>1987</year>
<volume>38</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>543-4</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rea]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Roche]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Finn]]></surname>
<given-names><![CDATA[D. P.]]></given-names>
</name>
</person-group>
<source><![CDATA[British Journal of Pharmacology]]></source>
<year>2007</year>
<volume>152</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>633-48</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sallan]]></surname>
<given-names><![CDATA[S. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Cronin]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Zelen]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Zinberg]]></surname>
<given-names><![CDATA[N. E.]]></given-names>
</name>
</person-group>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>1980</year>
<volume>302</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>135-8</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cannabinoids for cancer treatment: progress and promise]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarfaraz]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Adhami]]></surname>
<given-names><![CDATA[V. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Syed]]></surname>
<given-names><![CDATA[D. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Afaq]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Mukhtar]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Research]]></source>
<year>2008</year>
<volume>68</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>339-42</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steele]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Gralla]]></surname>
<given-names><![CDATA[R. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Braun Jr]]></surname>
<given-names><![CDATA[D. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[C. W.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Treatment Reports]]></source>
<year>1980</year>
<volume>64</volume>
<numero>2-3</numero>
<issue>2-3</issue>
<page-range>219-24</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strasser]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Luftner]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Possinger]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Ernst]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Ruhstaller]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Meissner]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Cerny]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Clinical Oncology]]></source>
<year>2006</year>
<volume>24</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>3394-400</page-range></nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Svendsen]]></surname>
<given-names><![CDATA[K. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[T. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Bach]]></surname>
<given-names><![CDATA[F. W.]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ]]></source>
<year>2004</year>
<volume>329</volume>
<numero>7460</numero>
<issue>7460</issue>
<page-range>253</page-range></nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Laar]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Cruts]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[van Ooyen-Houben]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Croes]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[van der Pol]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Meijer]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Ketelaars]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<source><![CDATA[The Netherlands drug situation 2014: Report to the EMCDDA]]></source>
<year>2015</year>
<publisher-name><![CDATA[Reitox National Focal Point]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer&#8217;s disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Volicer]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Stelly]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[McLaughlin]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Volicer]]></surname>
<given-names><![CDATA[B. J.]]></given-names>
</name>
</person-group>
<source><![CDATA[International Journal of Geriatric Psychiatry]]></source>
<year>1997</year>
<volume>12</volume>
<page-range>913-9</page-range></nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ware]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzcharles]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Joseph]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Shir]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Anesthesia &amp; Analgesia]]></source>
<year>2010</year>
<volume>110</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>604-10</page-range></nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. Journal of Neurology]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Goldman]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Truniger]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurosurgery &amp; Psychiatry]]></source>
<year>2010</year>
<volume>81</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1135-40</page-range></nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double&#8208;blind placebo&#8208;controlled cross&#8208;over trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wissel]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Haydn]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Brenneis]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Poewe]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Schelosky]]></surname>
<given-names><![CDATA[L. D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Neurology]]></source>
<year>2006</year>
<volume>253</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1337-41</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
